Published in J Clin Oncol on December 03, 2012
Adjuvant Radiation Therapy in Treating Patients With Brain Metastases | NCT00002899
Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol (2014) 4.37
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol (2015) 1.84
Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol (2014) 1.21
Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol (2014) 1.12
Progression-free survival benefit or health-related quality-of-life advantage: which one to choose? J Clin Oncol (2013) 0.99
Does quality of life supplant survival in patients with brain metastasis? J Clin Oncol (2013) 0.99
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro Oncol (2014) 0.98
Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. Radiat Oncol (2014) 0.96
Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc(-), leading to glutathione depletion. Oncogene (2015) 0.94
Targeted therapies in brain metastases. Curr Treat Options Neurol (2014) 0.93
On the merits and limitations of whole-brain radiation therapy. J Clin Oncol (2012) 0.93
Updates in the management of brain metastases. Neuro Oncol (2016) 0.88
Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids. Support Care Cancer (2013) 0.87
Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol (2013) 0.87
Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiat Oncol (2013) 0.86
Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy. Int J Mol Sci (2014) 0.86
Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer. Radiat Oncol J (2015) 0.85
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol (2015) 0.85
Gamma knife treatment of brainstem metastases. Int J Mol Sci (2014) 0.85
Stereotactic radiosurgery and stereotactic radiotherapy for brain metastases. Surg Neurol Int (2013) 0.83
Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach? Ann Transl Med (2016) 0.83
Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget (2016) 0.83
Hippocampal-avoidance whole-brain radiation therapy: a new standard for patients with brain metastases? J Clin Oncol (2014) 0.81
Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis (2015) 0.81
Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer. Int J Mol Sci (2014) 0.81
First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes (2015) 0.80
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J (2016) 0.79
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer (2013) 0.79
Stereotactic radiosurgery alone for small cell lung cancer: a neurocognitive benefit? Radiat Oncol (2014) 0.79
CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. J Neurooncol (2015) 0.79
Gamma knife radiosurgery treatment for metastatic melanoma of the trigeminal nerve and brainstem: a case report and a review of the literature. Case Rep Neurol Med (2013) 0.78
5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression. Oncotarget (2016) 0.78
Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study. Radiat Oncol (2015) 0.77
Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol (2016) 0.77
Radiosurgery to the Postoperative Tumor Bed for Metastatic Carcinoma Versus Whole Brain Radiation After Surgery. Cureus (2016) 0.77
Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol (2015) 0.77
Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway. Radiat Oncol (2014) 0.76
Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. Radiat Oncol (2015) 0.76
[Quality of life after surgery or radiosurgery of brain metastases and adjuvant whole brain radiotherapy. Short- and long-term prognosis differentiate the treatment strategy in brain metastases]. Strahlenther Onkol (2013) 0.75
Whole-brain radiation therapy for brain metastases: detrimental or beneficial? Radiat Oncol (2015) 0.75
Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis? Neuro Oncol (2016) 0.75
Reply to M.C. Chamberlain and C. Gemici. J Clin Oncol (2013) 0.75
Prevalence and predictors of fatigue in glioblastoma: a prospective study. Neuro Oncol (2014) 0.75
Clinical features of brain metastases in breast cancer: an implication for hippocampal-sparing whole-brain radiation therapy. Ther Clin Risk Manag (2016) 0.75
BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery. Front Oncol (2016) 0.75
The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations. Qual Life Res (2016) 0.75
Methods and results of local treatment of brain metastases in patients with breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res (2016) 0.75
Brain metastasis reirradiation in patients with advanced breast cancer. J Radiat Res (2016) 0.75
A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer Med (2017) 0.75
Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older. BMC Cancer (2016) 0.75
Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues. Neuro Oncol (2017) 0.75
Health-Related Quality of Life in Brain Tumor Patients Treated with Surgery: Preliminary Result of a Single Institution. Brain Tumor Res Treat (2016) 0.75
Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy. Transl Oncol (2016) 0.75
Novel risk stratification score for predicting early distant brain failure and salvage whole-brain radiotherapy after stereotactic radiosurgery for brain metastases. Cancer (2015) 0.75
Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro Oncol (2015) 0.75
Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiol Med (2017) 0.75
Distant brain recurrence in patients with five or more newly diagnosed brain metastases treated with focal stereotactic radiotherapy alone. J Radiosurg SBRT (2017) 0.75
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol (2017) 0.75
Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases. Cureus (2017) 0.75
Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery. Curr Oncol (2017) 0.75
Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases. Oncotarget (2016) 0.75
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 12.50
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol (2007) 7.51
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med (2009) 5.82
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med (2015) 5.08
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol (2006) 4.36
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med (2007) 3.97
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol (2005) 3.31
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol (2007) 2.90
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol (2007) 2.86
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty--angiographic and clinical follow-up in a prospective randomized controlled trial. Radiology (2004) 2.70
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol (2006) 2.66
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol (2009) 2.64
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol (2002) 2.63
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol (2004) 2.55
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer (2004) 2.41
A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol (2004) 2.36
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med (2003) 2.35
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Papillary tumor of the pineal region. Am J Surg Pathol (2003) 2.13
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys (2003) 2.10
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? BJU Int (2006) 2.03
Intracranial stereotactic radiosurgery with an adapted linear accelerator vs. robotic radiosurgery: Comparison of dosimetric treatment plan quality. Strahlenther Onkol (2014) 2.01
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95
What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol (2008) 1.88
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol (2006) 1.73
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica (2005) 1.66
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol (2006) 1.64
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys (2004) 1.62
Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer (2007) 1.62
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer (2008) 1.61
Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys (2013) 1.61
Fatigue in cancer survivors--prevalence and correlates. Onkologie (2009) 1.60
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2006) 1.51
Do quality-of-life randomized clinical trials support clinicians in their decision-making? J Clin Oncol (2002) 1.45
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 1.43
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys (2006) 1.42
Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J Clin Oncol (2007) 1.41
Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol (2007) 1.39
Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology (2002) 1.38
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol (2005) 1.38
Robot-assisted cystectomy: does it meet expectations? Eur Urol (2010) 1.37
Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol (2010) 1.36
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev (2006) 1.35
Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol (2008) 1.33
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys (2008) 1.33
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol (2002) 1.32
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol (2009) 1.30